DLL4 Antibody

中文名稱：

DLL4兔多克隆抗體
貨號：

CSB-PA831848
規格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using CSB-PA831848(DLL4 Antibody) at dilution 1/50, on the right is treated with fusion protein. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA831848(DLL4 Antibody) at dilution 1/50, on the right is treated with fusion protein. (Original magnification: ×200)
其他：

產品詳情
產品評價
相關產品
問答及客戶評論
靶點詳情

產品詳情

Uniprot No.：

Q9NR61
基因名：

DLL4
別名：

AOS6 antibody; Delta 4 antibody; delta 4 precursor antibody; Delta ligand 4 antibody; delta ligand 4 precursor antibody; Delta like 4 antibody; Delta like 4 homolog antibody; Delta like 4 protein antibody; Delta like canonical Notch ligand 4 antibody; Delta like protein 4 antibody; Delta-like 4 (Drosophila) antibody; Delta-like protein 4 antibody; Delta4 antibody; DLL 4 antibody; Dll4 antibody; DLL4_HUMAN antibody; Drosophila Delta homolog 4 antibody; hdelta2 antibody; Homeobox protein DLL-4 antibody; MGC126344 antibody; Notch ligand delta 2 antibody; Notch ligand DLL4 antibody; Notch ligand DLL4 precursor antibody; XDLL-4 antibody
宿主：

Rabbit
反應種屬：

Human,Mouse
免疫原：

Fusion protein of Human DLL4
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:10000
IHC	1:100-1:300

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

問答及客戶評論

■ 常見問題解答

我們課題組正在研究一種發育性疾病，并預期Dll4分布異常。CSB-PA831848 DLL4 Antibody是否與甲醇固定、4% PFA固定或小鼠樣本冷凍切片兼容?

CSB-PA831848 DLL4抗體的重要信息如下: 物種反應性:人、小鼠免疫原:人DLL4 C端135個氨基酸免疫原序列:　AVRQLRLRRPDDGSREAMNNLSDFQKDNLIPAAQLKNTNQKKELEVDCGLDKSNCGKQQNHTLDYNLAPGPLGRGTMPGKFPHSDKSLGEKAPLRLHSEKPECRISAICSPRDSMYQSVCLISEERNECVIATEV 小鼠與人的同源性為95.6%，因此理論上該CSB-PA831848 DLL4抗體適用于小鼠樣本。由于DLL4屬于膜蛋白，它與4% PFA固定兼容。然而，我們還沒有用冷凍切片進行驗證，所以我們不能保證測試結果。

收起更多

靶點詳情

功能：

Involved in the Notch signaling pathway as Notch ligand. Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types. During spinal cord neurogenesis, inhibits V2a interneuron fate.
基因功能參考文獻：
1. These data indicate that DLL4 represents a new prognostic biomarker for nonsmall cell lung cancer , and DLL4 overexpression inhibits cell proliferation and metastasis in vitro. PMID: 30226615
2. Study demonstrates that DLL4 is important in regulating the tumour growth of hepatitis B virus (HBV)-associated hepatocellular carcinoma as well as the neovascularization and suppression of HBV replication. PMID: 30228780
3. this study revealed that DLL4 has pathophysiological roles on the progression of esophagus cancer cells, including migration, invasion and apoptosis, which indicated that DLL4 may be considered as a potent therapeutic target for the treatment of malignant esophageal cancer. PMID: 29749499
4. The regulation of DLL4 by the LDB2 complex provides a novel mechanism of DLL4 transcriptional control that may be exploited to develop therapeutics for aberrant vascular remodeling. PMID: 28946938
5. Data show that Delta-like 4 (DLL4) and Jagged1 (JAG1) displayed equal potency in stimulating Notch target genes in HMEC-1 dermal microvascular endothelial cells but had opposing effects on sprouting angiogenesis in vitro. PMID: 28445154
6. epigenetic silencing and TP53 mutation have an effect on the expression of DLL4 in human cancer stem disorder PMID: 27542210
7. the Notch signaling and atherosclerosis relevant markers in lesions from femoral arteries of symptomatic peripheral artery disease patients, were characterized. PMID: 28472949
8. Data suggest that Numb acts as a Notch antagonist by controlling intracellular destination and stability of the Notch ligand Delta-like 4 (DLL4) through a post-endocytic sorting process; Numb negatively controls DLL4 plasma membrane recycling through well-documented recycling regulator protein AP1. PMID: 29042443
9. Results show that DLL4 is involved in SYNJ2BP-induced hepatocellular carcinoma (HCC) development though activating its pathway. PMID: 27440153
10. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with gallbladder cancers. PMID: 27174628
11. We show that GIT1, which also contains an ANK domain, inhibits the Notch1-Dll4 signaling pathway by competing with Notch1 ANK domain for binding to RBP-J in stalk cells PMID: 27926858
12. Results provide evidence that DLL4 is associated with gastric cancer stem/progenitor cells (GCSPCs), and its expression impacts CSPC stemness characteristics associated with the Notch-1 pathway including self-renewal, differentiation, proliferation, and tumor formation. PMID: 27891816
13. The authors present novel structures of human ligands Jagged2 and Delta-like4 and human Notch2, together with functional assays, which suggest that ligand-mediated coupling of membrane recognition and Notch binding is likely to be critical in establishing the optimal context for Notch signalling. PMID: 28572448
14. Overexpression of DLL4 could significantly attenuate the cytotoxic effects of docetaxel in MCF-7 cells by increasing Bcl-2 expression, while decreasing Bax expression, apoptosis rate and DNA damage PMID: 27334972
15. In gastric epithelial cells co-cultured with Helicobacter pylori, the expression level of the ligand DLL4 was found to be significantly increased. PMID: 27073072
16. Low DLL4 abundance in tumour cells may predict the benefit from adjuvant gemcitabine therapy after PDAC resection. PMID: 27755532
17. Angiogenesis in Infantile haemangioma (IH) appears to be controlled by DLL4 within the endothelium in a VEGF-A isoform-dependent manner, and in perivascular cells in a VEGF-independent manner. The contribution of VEGF-A isoforms to disease progression also indicates that IH may be associated with altered splicing. PMID: 26957058
18. Dll4 modulates liver inflammatory response by down-regulating chemokine expression PMID: 27171900
19. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with pancreatic ductal carcinoma. PMID: 27919854
20. Data show that the IgA/delta-like protein 4 (Delta-4)/Notch receptor (Notch) axis is not observed in IgG-dendritic cells (DCs). PMID: 27117596
21. Data suggest that the vascular DLL4-Notch4 signaling and VEGF signaling complementing each other plays an important role in the progression of tumor angiogenesis in primary glioblastoma. PMID: 26472724
22. our data indicate that high DLL4 expression predicts pelvic lymph node metastasis and poor survival in cervical cancer. Therefore, DLL4 may be a potential clinical diagnostic marker for patients with early-stage cervical cancer. PMID: 26546434
23. Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling PMID: 26870802
24. DLL4 and JAG1 may have opposing effects on tumor angiogenesis in glioblastoma. PMID: 26546995
25. Expression of D114 in the vessels of dermal microvasculature was shown to increase from 20 weeks of gestation to 20 years. PMID: 27487663
26. Data indicate the role for altered forkhead box C2 (FoxC2)-Delta-like ligand 4 (Dll4)signaling in structural alterations of saphenous veins in patients with varicose veins. PMID: 26808710
27. Antagonism of the DLL4-Notch signaling pathway might provide a potential therapeutic approach for breast cancer treatment by preventing angiogenesis. PMID: 26739060
28. Activation of Dll4/Notch signaling led to increased expression of ephrin-B2 and subsequent inhibition of endothelial progenitor cells activity. PMID: 26212082
29. DLL4 is a unique functional molecule of human circulating dendritic cells critical for directing Th1 and Th17 differentiation PMID: 26712946
30. The expression of DLL4 was positively correlated with CD105-labeled MVD. PMID: 25986715
31. The detection of Notch1 and Delta-like 4 expression in peripheral blood lymphocytes of renal transplant recipients can serve as a positive indicator for evaluating the diagnosis and treatment efficacy of the AR reaction. PMID: 26070613
32. Among all the Notch ligands, Delta-like4 (Dll4) is specifically involved in angiogenesis. hD4R could suppress angiogenesis in vitro as manifested by network formation assay and sprouting assay. PMID: 25833803
33. DLL4 and VEGFA expression was closely related to tumour diameter, clinical stage, histological grade and lymph node metastasis. PMID: 26111775
34. DLL4/Notch1 and BMP9 interdependent signaling induces endothelial cell quiescence via P27KIP1/thrombospondin pathway. PMID: 26471266
35. Overexpression of DLL4 is associated with thyroid tumor invasion and metastasis. PMID: 26241546
36. Macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells. PMID: 26404485
37. Heterozygous Loss-of-Function Mutations in DLL4 Cause Adams-Oliver Syndrome. PMID: 26299364
38. IL-23 could promote migration of human ESCC cells by activating DLL4/Notch1 signaling pathway PMID: 26062426
39. expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer PMID: 24949865
40. Dormant Dbf4 mRNA in immature GV oocytes is recruited by cytoplasmic polyadenylation during oocyte maturation and is dependent on MPF activity via its cytoplasmic polyadenylation element (CPE) PMID: 25348865
41. High DLL4 expression is associated with T acute lymphoblastic leukemia. PMID: 25355291
42. Inhibition of ADAM10/17 or knockdown of DLL4 reduced the proangiogenic effects of fibulin-3 in culture PMID: 25139440
43. Dll4 expression is up-regulated in clear cell renal cell carcinoma patients, and predicts poor prognosis. PMID: 24966922
44. Dengue virus up-regulates expression of notch ligands Dll1 and Dll4 through interferon-beta signalling pathway. PMID: 25041739
45. Our data suggest that renal cell carcinoma progression is caused in part by activated DLL4/Notch signaling, interaction of endothelium and cells PMID: 24931473
46. these results suggest that high expression of DLL4 is associated with axillary lymph node metastasis and a poor prognosis in breast cancer, suggesting its value as a diagnostic marker for breast cancer. PMID: 25260720
47. These findings indicate a potential role for the Notch-1-Dll4 signaling pathway in foreign body-induced granulomatous reactions PMID: 24394305
48. High expression of DLL4 is associated with metastasis in breast cancer. PMID: 24696220
49. findings suggest that ADAM10/Dll4 signaling is a major signaling pathway in ECs driving inflammatory events involved in inflammation and immune cell recruitment PMID: 25130545
50. Dll4-containing exosomes increase endothelial cell motility while suppressing their proliferation. PMID: 24504253
顯示更多

收起更多
相關疾病：

Adams-Oliver syndrome 6 (AOS6)
亞細胞定位：

Cell membrane; Single-pass type I membrane protein.
組織特異性：

Expressed in vascular endothelium.
數據庫鏈接：

HGNC: 2910

OMIM: 605185

KEGG: hsa:54567

STRING: 9606.ENSP00000249749

UniGene: Hs.511076

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human